Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. - Wikidata - awgldk - TriplyDB

Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis.

Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis.

http://www.wikidata.org/entity/Q31155014

about

Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin.Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke.Embryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion.Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2.Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.An association between gene expression and better survival in female mice following myocardial infarction.TLR2 and TLR4 mediate differential responses to limb ischemia through MyD88-dependent and independent pathways DDAH1 deficiency attenuates endothelial cell cycle progression and angiogenesis.Role of nitric oxide signaling in endothelial differentiation of embryonic stem cells Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance.Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.How to control NO production in cells: N(omega),N(omega)-dimethyl-L-arginine dimethylaminohydrolase as a novel drug target.Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1.Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.Effect of asymmetric dimethylarginine (ADMA) on heart failure development.Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.Overexpression of dimethylarginine dimethylaminohydrolase 1 attenuates airway inflammation in a mouse model of asthma Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production Microarray analysis for genes associated with angiogenesis in diabetic OLETF keratocytes.Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury.Perspective in chronic kidney disease: targeting hypoxia-inducible factor (HIF) as potential therapeutic approach.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.Redox regulation of gasotransmission in the vascular system: A focus on angiogenesis.NOx and ADMA changes with focal ischemia, amelioration with the chaperonin GroEL.The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis.Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis.Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular Hypertension Dimethylarginine dimethylaminohydrolase-2 deficiency promotes vascular regeneration and attenuates pathological angiogenesis.Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1.DDAH: a target for vascular therapy?Role of alanine:glyoxylate aminotransferase 2 in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy.Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.The evaluation of contralateral foot circulation after unilateral revascularization procedures using indocyanine green angiography.

P2860

Q28070134-1FE92B02-42ED-4F27-B98B-5EC2951009D5 Q28506246-FF7B452B-5F5D-4285-9A1F-3DBE908DD6B6 Q28581627-E69A5624-D983-4C67-AD6B-DE4B5D9D745B Q30423556-0419E021-0C9F-4EAD-9B59-1CA8E011C5EF Q33509022-1AC23C71-EECF-4AEA-93ED-A6D9A7CD5C39 Q33532341-0DD14763-9BC6-457C-81AC-5AECE65A6900 Q33589158-960B320D-5E32-4C79-A7D3-9E7F85539D27 Q33816492-33DB93A9-8AA9-4A8D-9872-3CB287B9D9C8 Q33904265-7762E7FB-D9A4-4CB1-97EA-A89343D6CD83 Q34205973-B7555912-111E-449C-8321-B99D3929F980 Q34500561-B21C2348-823B-43F1-99A1-A577FB3CB72C Q35048434-68C136A0-E3C9-4D5E-9B1F-12D6F10F7C5E Q35064180-82C4CEF2-1E28-479E-BD42-D79DE730CD76 Q35540671-D33EE00B-29D5-4253-93D4-1342BB99EC69 Q35933350-2288AE72-0C85-4AC2-9632-AFFEE4388F6C Q36438224-039EA934-B41E-41BE-8717-F3A900DCCD4F Q36471209-581093A9-19A6-4426-9D47-B51CCB026604 Q36590608-4B010208-AEC8-4EBB-82F6-BCE666CE5534 Q36997972-0888BB3B-57AB-4599-8929-89F0F516350F Q37245523-31835AD1-9690-4FA1-9E68-64980C89C0CD Q37370528-361893DA-9909-4442-BFEC-296831805413 Q37467533-F779A662-18DB-442B-BF0F-03DA7A99E578 Q37490288-207DDD79-A891-41AA-87AE-86A37C1859D2 Q37580114-F499A21F-D730-4D7D-9C32-926FD8F1E110 Q37583062-2081CD9B-14CA-4C2A-98C0-9F734D419594 Q37621347-882E054C-0E6E-47AC-9B2C-2DC2FF9379A3 Q37977513-BA277CD0-3C0F-44AC-849E-F8752F50D9E5 Q38203518-61FB1B74-70E8-4D63-A5DD-8C2920797B0E Q39256530-1FB6CA44-15BE-410F-97DC-B23AE7EAFFE8 Q39258680-44272057-6DA8-4B46-ADA1-656C167890B1 Q39523831-E5FA0855-A8F7-49A2-BE94-8C29EC8614FD Q40038186-D90CD942-4FA9-4EC7-A296-D77F7E024CD5 Q40969480-F17DA169-DB7A-45DE-B63B-F03AE192FA0E Q41870668-3AEEB717-F8AE-4DE1-B2F9-97B65FACB3E1 Q42513803-349FDB39-9501-4322-A554-5953E3EAF719 Q42630303-FA44B29C-FC2F-4EC8-B1C7-49F048E9C049 Q42716627-C36F65EC-2359-40C2-B8A5-9DACDB985083 Q43949655-9AB46BBC-4E99-41E6-B459-C0EC36654195 Q46982143-7A2E5852-7753-4603-8E69-3F75C5741C2E Q47139874-1A504FA9-9C66-4732-8CCD-92BD7DC37D0B

P2860

Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis.

http://www.wikidata.org/entity/Q31155014

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@ast

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@en

type

label

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@ast

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@en

prefLabel

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@ast

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@en

P1433

Q31155014-C33AB0AA-FFB9-4B13-BF6B-1FC4845BD483

P1476

Q31155014-12E6FD66-74AB-4D38-BFE8-4A5990543F0C

P2093

Q31155014-3609FB35-EEA7-4A3F-B618-9E93DF9FCDDD

Q31155014-38C3449D-C114-450F-8A5D-3C212313BE26

Q31155014-4180FFAB-C7CF-40A2-8D7B-4D76E4311768

Q31155014-42ABB5B7-1924-4751-8411-598C173D05B4

Q31155014-46D5DB98-74EE-483F-8D4D-80836AAB63F3

Q31155014-4E99F510-4BD2-4C76-A52A-B0B32EB32FE3

Q31155014-7ED6CCD8-29D9-4BCF-B772-A63FF31A4F56

Q31155014-98A8EC08-0CB4-497B-825A-5098050B3112

Q31155014-C1B0A356-AC7A-41FE-9232-D13DC4603347

Q31155014-C943AADD-07A8-4D14-9A53-F35AC6B6387C

P304

Q31155014-2A68AA13-24B0-476E-A56A-F28DF7C5BCD9

P31

Q31155014-5DC4A7E6-70A4-48E1-B8A2-8F1527910B71

P356

Q31155014-B3271B50-8FA3-4E8A-8990-562E9CA24786

P407

Q31155014-8EDB8DF2-3DA1-4CC5-8E36-B65B178B5D0F

P433

Q31155014-FEAF3166-E3D0-405F-AB09-582B4C2BE401

P478

Q31155014-BB780D5C-F22B-413E-846D-CEAF908AA51F

P577

Q31155014-462CC15E-228C-4A68-AF53-CDF4162F1A20

P5875

Q31155014-5D7A0D6A-A190-4CF9-906F-276C3136DC7F

P698

Q31155014-675D7639-3C77-4BAC-A167-5B515A11D8F6

P921

Q31155014-F0EF5C89-BD97-44C2-8C02-7E882FB392E3

P356

01.CIR.0000158487.80483.09

P1433

P1476

Overexpression of dimethylargi ...... els and enhances angiogenesis.

@en

P2093

Andrew J Patterson

http://www.w3.org/2001/XMLSchema#string

Bingyin Wang

http://www.w3.org/2001/XMLSchema#string

Georges von Degenfeld

http://www.w3.org/2001/XMLSchema#string

Hayan Dayoub

http://www.w3.org/2001/XMLSchema#string

Helen M Blau

http://www.w3.org/2001/XMLSchema#string

Johannes Jacobi

http://www.w3.org/2001/XMLSchema#string

John P Cooke

http://www.w3.org/2001/XMLSchema#string

Karsten Sydow

http://www.w3.org/2001/XMLSchema#string

Masumi Kimoto

http://www.w3.org/2001/XMLSchema#string

Ying Zhang

http://www.w3.org/2001/XMLSchema#string

P304

1431-1438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000158487.80483.09

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7952875

http://www.w3.org/2001/XMLSchema#string

P698

15781754

http://www.w3.org/2001/XMLSchema#string

P921